Dipartimento di Biochimica e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, 80131 Napoli, Italy.
Free Radic Biol Med. 2011 Sep 15;51(6):1126-36. doi: 10.1016/j.freeradbiomed.2011.05.040. Epub 2011 Jun 12.
Cross talk between unrelated cell surface receptors, such as G-protein-coupled receptors (GPCR) and receptor tyrosine kinases (RTK), is a crucial signaling mechanism to expand the cellular communication network. We investigated the ability of the GPCR formyl peptide receptor-like 1 (FPRL1) to transactivate the RTK epidermal growth factor receptor (EGFR) in CaLu-6 cells. We observed that stimulation with WKYMVm, an FPRL1 agonist isolated by screening synthetic peptide libraries, induces EGFR tyrosine phosphorylation, p47(phox) phosphorylation, NADPH-oxidase-dependent superoxide generation, and c-Src kinase activity. As a result of EGFR transactivation, phosphotyrosine residues provide docking sites for recruitment and triggering of the STAT3 pathway. WKYMVm-induced EGFR transactivation is prevented by the FPRL1-selective antagonist WRWWWW, by pertussis toxin (PTX), and by the c-Src inhibitor PP2. The critical role of NADPH-oxidase-dependent superoxide generation in this cross-talk mechanism is corroborated by the finding that apocynin or a siRNA against p22(phox) prevents EGFR transactivation and c-Src kinase activity. In addition, WKYMVm promotes CaLu-6 cell growth, which is prevented by PTX and by WRWWWW. These results highlight the role of FPRL1 as a potential target of new drugs and suggest that targeting both FPRL1 and EGFR may yield superior therapeutic effects compared with targeting either receptor separately.
细胞表面受体之间的串扰,如 G 蛋白偶联受体(GPCR)和受体酪氨酸激酶(RTK),是扩展细胞通讯网络的关键信号机制。我们研究了 GPCR 形式肽受体样 1(FPRL1)激活 RTK 表皮生长因子受体(EGFR)的能力在 CaLu-6 细胞中。我们观察到,用 WKYMVm 刺激,一种通过筛选合成肽文库分离的 FPRL1 激动剂,可诱导 EGFR 酪氨酸磷酸化、p47(phox)磷酸化、NADPH 氧化酶依赖性超氧化物生成和 c-Src 激酶活性。由于 EGFR 的转激活,磷酸酪氨酸残基提供了募集和触发 STAT3 途径的停靠位点。FPRL1 选择性拮抗剂 WRWWWW、百日咳毒素(PTX)和 c-Src 抑制剂 PP2 可阻止 WKYMVm 诱导的 EGFR 转激活。NADPH 氧化酶依赖性超氧化物生成在这种串扰机制中的关键作用得到了证实,即 apocynin 或针对 p22(phox)的 siRNA 可阻止 EGFR 转激活和 c-Src 激酶活性。此外,WKYMVm 促进 CaLu-6 细胞生长,PTX 和 WRWWWW 可阻止这种生长。这些结果突出了 FPRL1 作为新型药物潜在靶点的作用,并表明与单独靶向受体相比,靶向 FPRL1 和 EGFR 可能产生更好的治疗效果。